Mental Health

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

New migraine data builds on prior clinical studies in depression Migraine trial results Migraine trial results Depression trial results Depression...

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

Compass Health Center Announces Expansion to Maryland, Addressing Urgent Need for Quick Access to Comprehensive Mental Health Care In-Person and Virtually Across the State

Compass Health Center Extends Lifeline to Maryland Communities with Timely and Accessible Comprehensive Mental Health CareSILVER SPRING, MD / ACCESSWIRE...

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:...

error: Content is protected !!